Search results for "bowel"

showing 10 items of 637 documents

Risk of low bone mineral density and low body mass index in patients with non-celiac wheat-sensitivity: a prospective observation study.

2014

Background Non-celiac gluten sensitivity (NCGS) or ‘wheat sensitivity’ (NCWS) is included in the spectrum of gluten-related disorders. No data are available on the prevalence of low bone mass density (BMD) in NCWS. Our study aims to evaluate the prevalence of low BMD in NCWS patients and search for correlations with other clinical characteristics. Methods This prospective observation study included 75 NCWS patients (63 women; median age 36 years) with irritable bowel syndrome (IBS)-like symptoms, 65 IBS and 50 celiac controls. Patients were recruited at two Internal Medicine Departments. Elimination diet and double-blind placebo controlled (DBPC) wheat challenge proved the NCWS diagnosis. A…

AdultRiskmedicine.medical_specialtySettore MED/09 - Medicina InternaBone densityGlutensNon-celiac wheat sensitivityOsteoporosisGastroenterologyBody Mass IndexIrritable Bowel SyndromeYoung AdultDouble-Blind MethodBone DensityInternal medicineElimination dietmedicinePrevalenceHumansMultiple food allergyProspective StudiesProspective cohort studyIrritable bowel syndromeBone mineralMedicine(all)business.industryGeneral MedicineMiddle Agedmedicine.diseaseOsteopeniaBone Diseases MetabolicCeliac DiseaseIntestinal DiseasesEndocrinologyOsteoporosisnon-celiac wheat-sensitivityFemalebone mineral density; body mass index; non-celiac wheat-sensitivitybusinessbone mineral densityBody mass indexResearch ArticleBMC medicine
researchProduct

Information resources used by patients with inflammatory bowel disease: Satisfaction, expectations and information gaps.

2015

Abstract Background and purpose Information received by IBD patients about their disease is of particular importance. The objective of the study was to determine the information resources these patients used, together with their perceived information gaps and expected preferences. Patients and methods A prospective, observational, cross-sectional study conducted on IBD patients attending 13 Spanish hospitals during 2008. Patients completed a semi-structured 52-question survey. Results Survey was adequately completed by 379 of 385 patients (98%), of whom 57% had Crohn's disease and 43% ulcerative colitis. Mean patient age was 37.9 years (range, 16–76 years). Gastroenterologists were the most…

Adultmedicine.medical_specialtyAdolescentGeneral PracticeInformation Seeking BehaviorInformation needsDiseaseInflammatory bowel diseaseNurse's RoleYoung AdultPatient Education as TopicPatient ageSurveys and QuestionnairesmedicineHumansProspective StudiesPhysician's RoleAgedInternetHepatologybusiness.industryGastroenterologyMiddle Agedmedicine.diseaseInflammatory Bowel DiseasesUlcerative colitisSurgerySelf-Help GroupsCross-Sectional StudiesPatient SatisfactionFamily medicineObservational studybusinessGastroenterologia y hepatologia
researchProduct

6-thioguanosine diphosphate and triphosphate levels in red blood cells and response to azathioprine therapy in Crohn's disease.

2005

Background & Aims: Azathioprine is the gold standard for immunosuppressive therapy in Crohn's disease (CD) and its molecular mechanism of action is caused by the metabolite 6-thioguanosine triphosphate (TGTP). In this study we assessed the impact of TGTP levels for monitoring of azathioprine therapy. Methods: A novel, highly sensitive assay was established to measure levels of TGTP and its precursors 6-thioguanosine monophosphates and 6-thioguanosine diphosphates (TGDP) in red blood cells from 50 CD patients. The results were correlated with clinical outcome. Results: TGTP levels could be quantified in 47 patients and a subgroup of these patients showed significantly high levels of TGDP. 6-…

Adultmedicine.medical_specialtyErythrocytesMetaboliteAzathioprineInflammatory bowel diseaseGastroenterologyGuanosine Diphosphatechemistry.chemical_compoundCrohn DiseaseInternal medicineAzathioprinemedicineHumansCrohn's diseaseHepatologyThiopurine methyltransferasebiologybusiness.industryGastroenterologyAzathioprine therapyAntibodies MonoclonalThionucleotidesmedicine.diseaseInfliximabGuanine NucleotidesInfliximabRed blood cellmedicine.anatomical_structurechemistryImmunologybiology.proteinbusinessBiomarkersImmunosuppressive Agentsmedicine.drugClinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
researchProduct

Second European evidence-based consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease

2014

The treatment of inflammatory bowel disease (IBD) has been revolutionised over the past decade by the increasing use of immunomodulators, mainly azathioprine (AZA)/6-mercaptopurine (6-MP) and methotrexate (MTX), together with the advent of biological therapy. Immunomodulators are being used more often and earlier in the course of the disease.1 The introduction of biologic agents, especially inhibitors of the key proinflammatory cytokine, tumor necrosis factor alpha (TNF-α) initiated a new therapeutic era, whose use has grown continuously since their introduction in 1998.2 With such immunomodulation, the potential for opportunistic infection is a key safety concern for patients with IBD. Opp…

Adultmedicine.medical_specialtyEvidence-based practiceAdolescentOpportunistic infectionSettore MED/12 - GASTROENTEROLOGIAMEDLINEAzathioprineHIV InfectionsSettore MED/17 - MALATTIE INFETTIVEInflammatory bowel diseaseInflammatory bowel diseaseImmunocompromised HostYoung AdultRisk FactorsInfluenza HumanmedicineParasitic DiseasesHumansOpportunistic infectionsIntensive care medicineECCO guidelinesIrritable bowel syndromebusiness.industryPapillomavirus InfectionsGastroenterologyAge FactorsGeneral MedicineHerpesviridae InfectionsMiddle Agedmedicine.diseaseHepatitis BInflammatory Bowel DiseasesHepatitis CVaccinationMycosesInfectious disease (medical specialty)ImmunologyHuman medicinebusinessmedicine.drug
researchProduct

Gynecological Disorders in Patients with Non-celiac Wheat Sensitivity

2019

Background: Non-celiac wheat sensitivity (NCWS) most frequently presents clinically with irritable bowel syndrome (IBS)-like symptoms, although many extra-intestinal manifestations have also been attributed to it. No studies to date have evaluated the presence and frequency of gynecological symptoms in NCWS. Aim: To evaluate the frequency of gynecological disorders in patients with NCWS. Patients and Methods: Sixty-eight women with NCWS were included in the study. A questionnaire investigating gynecological symptoms and recurrent cystitis was administered, and patients reporting symptoms were then examined by specialists. Three control groups were selected: 52 patients with IBS not related …

Adultmedicine.medical_specialtySettore MED/09 - Medicina InternaPhysiologyNon-celiac wheat sensitivitymedia_common.quotation_subjectCystitiDiseaseWheat HypersensitivityGastroenterology03 medical and health sciencesDiet Gluten-FreeYoung Adult0302 clinical medicineInternal medicineCystitismedicineHumansIn patientGynecological disordersProspective StudiesVaginitisIrritable bowel syndromeMenstrual cycleVaginitismedia_commonbusiness.industryMenstrual cycle abnormalitieGastroenterologyHepatologyMiddle Agedmedicine.diseaseCeliac DiseaseIrritable bowel syndrome030220 oncology & carcinogenesisRecurrent cystitis030211 gastroenterology & hepatologyFemaleObstetric diseasebusinessFollow-Up Studies
researchProduct

Definition of a dynamic laparoscopic model for the prediction of incomplete cytoreduction in advanced epithelial ovarian cancer: Proof of a concept

2015

Abstract Objective To develop an updated laparoscopy-based model to predict incomplete cytoreduction (RT>0) in advanced epithelial ovarian cancer (AEOC), after the introduction of upper abdominal surgery (UAS). Patients and methods The presence of omental cake, peritoneal extensive carcinomatosis, diaphragmatic confluent carcinomatosis, bowel infiltration, stomach and/or spleen and/or lesser omentum infiltration, and superficial liver metastases was evaluated by staging laparoscopy (S-LPS) in a consecutive series of 234 women with newly diagnosed AEOC, receiving laparotomic PDS after S-LPS. Parameters showing a specificity≥75%, PPV≥50%, and NPV≥50% received 1 point score, with an additional…

Adultmedicine.medical_specialtymedicine.medical_treatmentOmental cakePredictive Value of TestCarcinoma Ovarian EpithelialModels BiologicallaparoscopicGynecologic Surgical ProceduresGynecologic Surgical ProcedureRetrospective StudiePredictive Value of TestsLaparotomymedicineHumansNeoplasms Glandular and EpithelialLaparoscopyAgedNeoplasm StagingRetrospective StudiesLesser omentumPrimary debulking surgeryAged 80 and overOvarian Neoplasmsmedicine.diagnostic_testbusiness.industryStomachOvarian NeoplasmMedicine (all)Obstetrics and GynecologyBowel resectionMiddle Agedmedicine.diseaseAdvanced epithelial ovarian cancerSurgerymedicine.anatomical_structureovarian cancerSettore MED/40 - GINECOLOGIA E OSTETRICIAOncologyPredictive value of testsFemaleLaparoscopyOvarian cancerbusinessHuman
researchProduct

The atypical cannabinoid O-1602 protects against experimental colitis and inhibits neutrophil recruitment.

2011

Background: Cannabinoids are known to reduce intestinal inflammation. Atypical cannabinoids produce pharmacological effects via unidentified targets. We were interested in whether the atypical cannabinoid O-1602, reportedly an agonist of the putative cannabinoid receptor GPR55, reduces disease severity of dextran sulfate sodium (DSS) and trinitrobenzene sulfonic acid (TNBS)-induced colitis in C57BL/6N and CD1 mice. Methods: DSS (2.5% and 4%) was supplied in drinking water for 1 week while TNBS (4 mg) was applied as a single intrarectal bolus. Results: Both treatments caused severe colitis. Injection of O-1602 (5 mg/kg intraperitoneally) significantly reduced macroscopic and histological col…

AgonistMaleCannabinoid receptormedicine.drug_classColonNeutrophilsmedicine.medical_treatmentPharmacologyMotor ActivityInflammatory bowel diseaseArticleReceptors G-Protein-CoupledReceptor Cannabinoid CB2chemistry.chemical_compoundMiceReceptor Cannabinoid CB1CyclohexanesmedicineImmunology and AllergyAnimalsCannabidiolColitisReceptorReceptors CannabinoidPeroxidaseMice KnockoutAnalysis of VarianceO-1602business.industryCannabinoidsDextran SulfateGastroenterologyResorcinolsmedicine.diseaseColitisMice Inbred C57BLChemotaxis LeukocyteDisease Models AnimalchemistryGPR55Neutrophil InfiltrationTrinitrobenzenesulfonic AcidImmunologylipids (amino acids peptides and proteins)CannabinoidbusinessInflammatory bowel diseases
researchProduct

GLP-2: What do we know? What are we going to discover?

2014

Glucagon-like peptide 2 [GLP-2] is a 33-amino acid peptide released from the mucosal enteroendocrine L-cells of the intestine. The actions of GLP-2 are transduced by the GLP-2 receptor [GLP-2R], which is localized in the neurons of the enteric nervous system but not in the intestinal epithelium, indicating an indirect mechanism of action. GLP-2 is well known for its trophic role within the intestine and interest in GLP-2 is now reviving based on the approval of the GLP-2R agonist for treatment of short bowel syndrome [SBS]. Recently it also seems to be involved in glucose homeostasis. The aim of this review is to outline the importance of neuroendocrine peptides, specifically of GLP-2 in th…

Agonistendocrine systemmedicine.medical_specialtyPhysiologymedicine.drug_classClinical BiochemistryEnteroendocrine cellBiologySettore BIO/09 - FisiologiaBiochemistryEnteric Nervous SystemCellular and Molecular NeuroscienceEndocrinologyInternal medicineGlucagon-Like Peptide 2medicineAnimalsHumansGlucose homeostasisReceptorInflammationdigestive oral and skin physiologyShort bowel syndromemedicine.diseaseIntestinal epitheliumGastrointestinal TractEndocrinologyGLP-2 GLP-2 receptor gastrointestinal tract enteric nervous systemEnteric nervous systemGastrointestinal functionNeurosciencehormones hormone substitutes and hormone antagonistsSignal TransductionRegulatory Peptides
researchProduct

Interoceptive Abilities in Inflammatory Bowel Diseases and Irritable Bowel Syndrome

2020

International audience; Alexithymia is usually described by three main dimensions difficulty identifying feelings (DIF), difficulty describing feelings (DDF), and externally oriented thinking (EOT). The most commonly used questionnaire investigating alexithymia, the Toronto Alexithymia Scale (TAS-20), supports this three-factor structure. One important assumption is that alexithymia severity is associated to vulnerability to somatic diseases, among them gastrointestinal disorders. However, the association between alexithymia and gastrointestinal disorders is not systematic, thus questioning the role of alexithymia as a vulnerability factor for those illnesses. A recent factor analysis sugge…

Alexithymialcsh:RC435-571DiseaseInflammatory bowel diseaseInflammatory bowel disease03 medical and health sciencesToronto Alexithymia Scale0302 clinical medicineAlexithymiainflammatory bowel diseaselcsh:PsychiatrymedicineIrritable bowel syndromeDepression (differential diagnoses)Original Researchirritable bowel syndromePsychiatry[SDV.MHEP] Life Sciences [q-bio]/Human health and pathologymedicine.diagnostic_testbusiness.industryinteroceptive abilities[SDV.MHEP.HEG]Life Sciences [q-bio]/Human health and pathology/Hépatology and Gastroenterologymedicine.disease[SDV.MHEP.HEG] Life Sciences [q-bio]/Human health and pathology/Hépatology and Gastroenterology030227 psychiatryPsychiatry and Mental healthIrritable bowel syndromemedicine.anatomical_structureHypothalamic-pituitary adrenal axis[SCCO.PSYC]Cognitive science/Psychology[SCCO.PSYC] Cognitive science/PsychologyAnxietyInteroceptive abilitiesalexithymiahypothalamic-pituitary adrenal axismedicine.symptombusiness030217 neurology & neurosurgeryHypothalamic–pituitary–adrenal axis[SDV.MHEP]Life Sciences [q-bio]/Human health and pathologyClinical psychology
researchProduct

Mucosal immunoregulation: transcription factors as possible therapeutic targets.

2005

Much progress has been recently made with regard to our understanding of the mucosal immune system in health and disease. In particular, it has been shown that uncontrolled mucosal immune responses driven by lymphocytes or non-lymphoid cells may lead to immunological diseases such as allergy, hypersensitivity and inflammation. Thus, a more detailed understanding of mucosal immune regulation and decision making at mucosal surfaces is essential for a better understanding of mucosal immune responses in health and disease. Antigen presenting cells and T lymphocytes play a key role in controlling mucosal immune responses. To deal with this key task, T helper cells differentiate into functionally…

AllergyImmunologyInflammationApoptosisSuppressor of Cytokine Signaling ProteinsAllergic inflammationPathogenesisImmune systemImmunitymedicineHypersensitivityImmunology and AllergyAnimalsHumansIL-2 receptorMast CellsAntigen-presenting cellGlucocorticoidsImmunity MucosalPharmacologybusiness.industrymedicine.diseaseInflammatory Bowel DiseasesAsthmaIntestinesSuppressor of Cytokine Signaling 3 ProteinImmunologyCytokinesmedicine.symptombusinessTranscription FactorsCurrent drug targets. Inflammation and allergy
researchProduct